Early Access — free while we kick the tires
EdgarHawk

Katkin Keith

Director

Director
1 filing analyzed · 1 company · Latest 2025-05-19

Never miss a filing from Katkin Keith

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Syndax Pharmaceuticals Inc SNDX 1 0 Net buying

Activity

May 2025
high
Buy
10,000 shares
$91,120
Significance 6/10

Director Keith Katkin bought 10,000 shares of SNDX at $9.11; 3 other insiders bought within 14 days amid -62.5% from 52-week high.

Director Keith Katkin purchased 10,000 shares at $9.11 on 2025-05-19, increasing his holdings by 11.1% to 100,000 shares total. This purchase occurs within a cluster pattern: 3 other insiders also bought within the past 14 days. The stock is trading at $9.30, down 62.5% from its 52-week high of $24.81 and down 36.4% over the past 90 days. The company reported revenue of $20,042,000.00 in its latest quarter but is unprofitable with a net loss of $84,846,000.00 over its most recent fiscal year. The coordinated buying activity at a depressed price level, combined with the company's significant losses, warrants examination of whether insiders perceive the current valuation as disconnected from near-term operational performance, or whether additional strategic context is driving the transactions.

Related insiders